Physician profile
Maya Barghash
NPI 1154563021
$4,519.18
in general payments reported to CMS, 2019-2025
18 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.67 · 2021: $290 · 2022: $986 · 2023: $923 · 2024: $1,096 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,115.46 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $532.28 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $495.15 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.61 | 2022-2024 | Camzyos |
| Boston Scientific Corporation | $256.11 | 2022 | |
| Cvrx, INC. | $140.24 | 2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.14 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $118.65 | 2023-2025 | Farxiga, Wainua, Lokelma |
| Alnylam Pharmaceuticals INC. | $81.28 | 2023-2025 | Amvuttra, Onpattro |
| Amgen INC. | $70.01 | 2024 | Repatha |
| Pfizer INC. | $54.71 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $48.94 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $47.66 | 2023 | Verquvo |
| Novo Nordisk INC | $32.22 | 2025 | Wegovy |
| Heartflow, INC. | $22.85 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $22.45 | 2025 | |
| Lilly USA, LLC | $19.53 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $17.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Barghash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.